Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Adv Biol (Weinh). 2022 Oct;6(10):e2200093. doi: 10.1002/adbi.202200093. Epub 2022 Jun 8.
Triacylglycerol (TG) metabolism is tightly regulated to maintain a pool of TG within circulating lipoproteins that can be hydrolyzed in a tissue-specific manner by lipoprotein lipase (LPL) to enable the delivery of fatty acids to adipose or oxidative tissues as needed. Elevated serum TG concentrations, which result from a deficiency of LPL activity or, more commonly, an imbalance in the regulation of tissue-specific LPL activities, have been associated with an increased risk of atherosclerotic cardiovascular disease through multiple studies. Among the most critical LPL regulators are the angiopoietin-like (ANGPTL) proteins ANGPTL3, ANGPTL4, and ANGPTL8, and a number of different apolipoproteins including apolipoprotein A5 (ApoA5), apolipoprotein C2 (ApoC2), and apolipoprotein C3 (ApoC3). These ANGPTLs and apolipoproteins work together to orchestrate LPL activity and therefore play pivotal roles in TG partitioning, hydrolysis, and utilization. This review summarizes the mechanisms of action, epidemiological findings, and genetic data most relevant to these ANGPTLs and apolipoproteins. The interplay between these important regulators of TG metabolism in both fasted and fed states is highlighted with a holistic view toward understanding key concepts and interactions. Strategies for developing safe and effective therapeutics to reduce circulating TG by selectively targeting these ANGPTLs and apolipoproteins are also discussed.
甘油三酯(TG)代谢受到严格调控,以维持循环脂蛋白中的 TG 池,脂蛋白脂肪酶(LPL)可特异性水解该池中的 TG,从而按需将脂肪酸输送至脂肪组织或氧化组织。多项研究表明,由于 LPL 活性缺乏或更常见的是组织特异性 LPL 活性调节失衡,导致血清 TG 浓度升高,与动脉粥样硬化性心血管疾病风险增加相关。LPL 最重要的调节因子包括血管生成素样(ANGPTL)蛋白 ANGPTL3、ANGPTL4 和 ANGPTL8,以及多种不同的载脂蛋白,包括载脂蛋白 A5(ApoA5)、载脂蛋白 C2(ApoC2)和载脂蛋白 C3(ApoC3)。这些 ANGPTLs 和载脂蛋白共同作用以协调 LPL 活性,因此在 TG 分配、水解和利用中发挥关键作用。本综述总结了这些与 ANGPTLs 和载脂蛋白相关的作用机制、流行病学研究结果和遗传数据。从整体角度重点阐述了这些 TG 代谢重要调节剂在空腹和进食状态下的相互作用,以深入了解关键概念和相互作用。还讨论了通过选择性靶向这些 ANGPTLs 和载脂蛋白来开发安全有效的治疗方法以降低循环 TG 的策略。